Trial document

This trial has been registered retrospectively.
drksid header


Trial Description

start of 1:1-Block title


Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The treatment of the mammacarcinoma consists in this study normally on 6 chemotherapy cycles of the combination Docetaxel, Epirubicine and Cyclophosphamide (TEC-therapy). Followed by the surgery of the carcinoma, which takes place on day 28 after the last chemotherapy application, at the latest. An evaluation of the response of the treatment is performed after 2 and 4 cycles by use of palpation and mamma sonography. In case of complete remission, partial remission and no change the patient receives further two TEC cycles. In case of progress under therapy the surgery is immediately performed.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Clinical studies have shown an equale effect in recurrence-free and total survival for neoadjuvant and adjuvant chemotherapies in patients with mammacarcinoma.
The primary systemic therapy allows an immediate evalution of the tumor response due to the treatment, this result is a important parameter in the prognosis of mammacarcinoma.
Pathologically proven complete remission are associated with a significant higher disease-free survival.
When giving a patient a primary systemic chemotherapie, the focus lies on the increase of the amount of breast preserving therapies and the toxicity profile of a chemotherapy and its tolerance, respectively.
The combination of Docetaxel, Epirubicine and Cyclophosphamide in this setting was so far little investigated.
The dose of TEC used in this study was chosen according to study results available so far especially from the adjuvant therapies.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000162
  •   2009/07/20
  •   [---]*
  •   yes
  •   Approved
  •   EK-AMG-MCF-25108-1, Ethikkommission bei der Sächsischen Landesärztekammer
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1111-3764 
  •   2008-003064-19 
  •   4034658 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   10006187: Primary mamma carcinoma
  •   C50 -  Malignant neoplasm of breast
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   neoadjuvant chemotherapy
    6 cycles a:
    Docetaxel: 75 mg/m square
    Epirubicine: 75 mg/m square
    Cyclophosphamide 500 mg/m square

    and breast surgery
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Other
  •   Single (group)
  •   IIb
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Estimation of the complete remission rate of invasive tumor cells in the breast confirmed by histological examinations, at surgery.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Tumor response according to clinical criteria determined by sonogrphy at surgery.
Tumor response according to pathological criteria determined by histology at surgery.
Rate of breast-conserving surgery
Toxicity associated with the therapy at each performed chemotherapy cycle.
Disease free survival until study end
Overall survival until study end

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2009/03/23
  •   150
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Women with histologically verified mamma carcinoma (assessment of estrogen and progesterone receptors, grading, negative HER-2/neu status)
- All receptor-negative mamma carcinoma starting from cT1c, all receptor-positive mamma carcinoma starting from cT3, cT4 includes inflammatory mamma carcinoma
- In case of cT2 and receptor-positivity, N+ is required and can also be detected with sentinel node biopsy
- In case of cT1c and receptor-positivity, a positive lymph node must be verified with sentinel node biopsy (pNsn+)
- Clinically and with an imaging technology (sonography or mammography) measurable primary tumor
- Sufficient bone marrow reserve: number of neutrophils higher/equal 1,5 x 1000000000/L, number of thrombocytes higher/equal 100 x 1000000000/L, hemoglobin higher/equal 6,2 mmol/L
- Sufficient liver and renal function: bilirubin smaller/equal 1 x upper limit of quantification (ULQ), ASAT (SGOT) and ALAT (SGPT) smaller 1,5 x ULQ, alcalic phosphatase smaller 1,5 x ULQ, Creatinine smaller 1 x ULQ (if creatinine higher ULQ creatinine clearance must be higher 60 mL/minute)
- Age-appropriate cardiologically normal findings as documented by ECG and LVEF (echocardiographical) assessments before beginning the therapy
- ECOG-performance-status of 0-2
- Age greater/equal 18 years
- Written informed consent of the patient including compliance of the patient regarding the therapy and the follow-up must be available before enrolment and documented according to the local regulations.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Pregnant or nursing women. Positive pregnancy test (urine or serum) within 7 days before registration
- Previous surgical, cytostatic or hormonal therapy (with exception of hormone substitution or contraception), no previous immune or radiation therapy
- Women with child bearing potency (menopause according to hormone status) without effective non-hormonal contraception (intra-uterine devices such as spirals, condoms in combination with additional contraceptic measures, vasectomised partner) during the participation in the study and 6 months after the end of study therapy.
- Bilateral localisation of tumors
- Evidence of distant metastases after complete staging with chest X-ray, upper abdomen sonography, and/or CT and bone scintigraphy
- Pre-existing motor or sensor neurotoxicity > grade 2 (according to NCl criteria)
- Pre-existing cardiac disease not permitting the participation in this study (e.g. severe heart insufficiency or unstable angina pectoris, cardiac infarction within one year before study entry, uncontrolled hypertension, therapy resistant arrhythmia
- Significant neurological or psychiatric disease in the anamnesis (including psychotic disorders, dementia or seizures) compromising the understanding of the trial and consent to the trial.
- Drug abuse
- Active infection
- Florid ulcus, unstable diabetes mellitus
- Previously diagnosed tumor with exception of basalioma or in situ carcinoma of the cervix or other cancers having been treated curatively and having been followed by a disease-free interval of < 10 years.
- Chronic treatment with corticosteroids if not started > 6 months before study entry and at low doses (< 20 mg Methylprednisolone or equivalents)
- Clear contraindication for the application of corticosteroids
- Contraindication of the planned therapy:
- hypersensitivity to one of the trial drugs (Docetaxel, Cyclophosphamide and Epirubicine)
- extensive inflammatory condition of oral or gastrointestinal mucous membrane
- Lack of compliance
- Concomitant participation in other clinical trials

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Universität Leipzig
    • Ms.  Dr. med.  Susanne  Briest 
    • Brustzentrum Leipzig, Liebigstr. 20
    • 04103  Leipzig
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Koordinierungszentrum für Klinische Studien Leipzig
    • Ms.  Dr. med.  Anja  Broda 
    • Härtelstr. 16-18
    • 04107  Leipzig
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Krankenhaus St. Elisabeth Leipzig
    • Ms.  Dr. med.  Dagmar  Langanke 
    • Biedermannstr. 84
    • 04277  Leipzig
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Sanofi-Aventis Deutschland GmbH
    • Potsdamer Str. 8
    • 10785  Berlin
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • AMGEN GmbH
    • Hanauer Straße 1
    • 80992  München
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2016/07/07
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Senologie - Zeitschrift für Mammadiagnostik und -therapie 2012; 9 - A98. Erste Ergebnisse der Phase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER-2 neu negativem Mammakarzinom (NeoTEC-Studie), D Langanke 1, U Wolfeneck 1, A Franke
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.